A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.10.016
Abstract: PURPOSE Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation. METHODS This was… read more here.
Keywords: met amplification; kinase inhibitor; selective met; patients advanced ... See more keywords
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "ESMO open"
DOI: 10.1016/j.esmoop.2021.100319
Abstract: The rapidly changing treatment paradigm for patients with metastatic oncogene-driven lung cancer continues to evolve, and consequently our understanding of the landscape of resistance must also advance. MET amplification is an established and frequent driver… read more here.
Keywords: met amplification; driver; resistance; lung cancer ... See more keywords
Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Investigation"
DOI: 10.1080/07357907.2021.1884695
Abstract: Abstract Comprehensive molecular testing of individual tumors has led to the identification of novel molecularly defined cancer therapies and treatment indications. Given low frequencies of many molecular alterations, efficacy of therapies used to target them… read more here.
Keywords: met amplification; sinonasal undifferentiated; case; undifferentiated carcinoma ... See more keywords
Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz431.004
Abstract: Abstract Background MET amplification is a rare genetic mutation which can be treated with small-molecule inhibitor-crizotinib. Based on the detection of next-generation sequencing, the molecular characteristics and the efficacy of crizotinib among different subsets of… read more here.
Keywords: met amplification; crizotinib among; efficacy crizotinib; next generation ... See more keywords
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14593
Abstract: The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its… read more here.
Keywords: treated erlotinib; egfr; met amplification; responses osimertinib ... See more keywords
Abstract 1652: Preclinical characterization of ICT-011, a first-in-class, highly selective, potent and orally bioavailable MET degrader for the treatment of NSCLC harboring MET amplification
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-1652
Abstract: The MET (also known as c-MET) tyrosine kinase receptor plays important roles in cancer cell growth, survival, migration, and invasion/metastasis. More importantly, MET alterations, including MET gene exon 14 skipping mutation, amplification and protein overexpression… read more here.
Keywords: treatment nsclc; met amplification; ict 011; amplification ... See more keywords
Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study
Sign Up to like & getrecommendations! Published in 2024 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359241229435
Abstract: Background: Mesenchymal–epithelial transition (MET) amplification is a crucial oncogenic driver and a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) of non-small-cell lung cancer (NSCLC). Fluorescence in situ hybridization (FISH) is the… read more here.
Keywords: nsclc patients; detection; plasma ddpcr; met amplification ... See more keywords
INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification
Sign Up to like & getrecommendations! Published in 2019 at "BMC Research Notes"
DOI: 10.1186/s13104-019-4163-x
Abstract: ObjectiveGastric cancer is more open related to genetic predisposition. In our RNA sequencing study on gastric cancer patients, Runt-related transcription factor-3 (RUNX3) expression was significantly down-regulated in gastric cancer. We showed that decreased levels of… read more here.
Keywords: diffuse; gastric cancer; met amplification; inc280 inhibits ... See more keywords
Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2018.00305
Abstract: MET amplification is rare in treatment-naïve metastatic colorectal cancer (CRC) tumors, but can emerge as a mechanism of resistance to anti-EGFR therapies. Preclinical and clinical data suggest that patients with MET amplified tumors benefit from… read more here.
Keywords: metastatic colorectal; response; met amplification; treatment ... See more keywords
Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.645224
Abstract: Background Although C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired resistance mechanisms include a second… read more here.
Keywords: met amplification; ros1 rearranged; resistance; case ... See more keywords
Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1450855
Abstract: Background The distant metastasis of lung cancer primarily occurs in the bones, liver, brain, and lungs, while the breast is an extremely rare site of metastasis. There is very limited literature on the occurrence of… read more here.
Keywords: treatment; breast; lung adenocarcinoma; met amplification ... See more keywords